DB18661ApprovedVaccines
Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen is a component of a live attenuated influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.
- First approval
- United States, 2023
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which companies are running trials of Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account